FOLH1 and neoplasm: Namely, in the intra-individual comparisons involving 33 patients with mCRPC, we evaluated the relationship of changes in tumor burden effected by 177Lu-PSMA-617 RLT with changes in radiopharmaceutical uptake in key organs-at-risk in patients receiving such treatment.